Interaction of intravitreal combination drugs and the effect on the targeted site

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 5, 2009, Pages 387-394

  Peyman, Gholam A ^a,b   Conway, Mandi D ^a,b   Fiscella, Richard ^c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADALIMUMAB; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ASCORBIC ACID; BICARBONATE; CEFTAZIDIME; CHONDROITIN SULFATE; CIPROFLOXACIN; CLINDAMYCIN; CYCLOSPORIN; DEXAMETHASONE; DICLOFENAC; DOXYCYCLINE; ETANERCEPT; FLURBIPROFEN; FOSCARNET; GANCICLOVIR; HYALURONIC ACID; INFLIXIMAB; KETOROLAC; RAPAMYCIN; SODIUM DIHYDROGEN PHOSPHATE; SODIUM METABISULFITE; SODIUM THIOSULFATE; TACROLIMUS; TISSUE PLASMINOGEN ACTIVATOR; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; VANCOMYCIN;

COMBINATION CHEMOTHERAPY; DRUG INTERACTION; DRUG TOXICITY; EYE DISEASE; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; KERATOPATHY; PHACOEMULSIFICATION; PRECIPITATION; REVIEW;

DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EYE DISEASES; HUMANS; INJECTIONS; OPHTHALMIC SOLUTIONS; VITREOUS BODY;

EID: 70350445522     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0027     Document Type: Review

References (95)

1. Peyman, G.A., Spitznas, M., and Straatsma, B.R. Chorioretinal diffusion of peroxidase before and after photocoagulation. Invest. Ophthalmol. 10:489-495, 1971.
2. Peyman, G.A., Vastine, D.W., Crouch, E.R., et al. Clinical use of intravitreal antibiotics to treat bacterial endophthalmitis. Trans. Acad. Ophthalmol. Otolaryngol. 78:OP862-OP875, 1974.
3. Newton, D.W. Introduction. In: Trissel, L.A., ed. Handbook on Injectable Drugs. 3rd ed. Bethesda, MD: American Society of Hospital Pharmacists, Inc.; 1983; p. XI-XXI.
4. Nevyas, A.S., Raber, I.M., Eagle, R.C., et al. Acute band keratopathy following intracameral Viscoat. Arch. Ophthalmol. 105:958-964, 1987.
5. Jensen, M., Crandall, A.S., Mamalis, N., et al. Crystallization on intraocular lens surfaces associated with the use of Healon, G.V. Arch. Ophthalmol. 112:1037-1042, 1994.
6. Ward, C., and Weck, S. Dilution and storage of recombinant tissue plasminogen activator (Activase) in balanced salt solutions. Am. J. Ophthalmol. 109:98-99, 1990.
7. Edelhauser, H.F., Hyndiuk, R.A., Zeeb, A., et al. Corneal edema and the intraocular use of epinephrine. Am. J. Ophthalmol. 93:327-333, 1982.
8. Wilhelmus, K.R., and Abshire, R.L. Corneal ciprofloxacin precipitation during bacterial keratitis. Am. J. Ophthalmol. 136:1032-1037, 2003.
9. Hui, M., Kwok, A.K., Pang, C.P., et al. An in vitro study on the compatibility and precipitation of a combination of cipro- floxacin and vancomycin in human vitreous. Br. J. Ophthalmol. 88:218-222, 2004.
10. Fiscella, R.G. Physical incompatibility of vancomycin and ceftazidime for intravitreal injection. Arch. Ophthalmol. 111:730, 1993.
11. Raju, B., Bali, T., Thiagarajan, G., et al. Physicochemical properties and antibacterial activity of the precipitate of vancomycin and ceftazidime. Retina. 28:320-325, 2008.
12. Conway, M.D., Jermak, C.M., Peyman, G.A., et al. Buffering capacity of bovine vitreous. Retina. 28:150-153, 2008.
13. Peyman, G.A., and Herbst, R. Bacterial endophthalmitis: Treatment with intraocular injection of gentamicin and dexamethasone. Arch. Ophthalmol. 91:416-418, 1974.
14. Paque, J.T., and Peyman, G.A. Intravitreal clindamycin phosphate in the treatment of vitreous infection. Ophthalmic. Surg. 5:34-39, 1974.
15. Homer, P., Peyman, G.A., Koziol, J., et al. Intravitreal injection of vancomycin in experimental staphylococcal endophthalmitis. Acta Ophthalmol. 53:311-320, 1975.
16. Peyman, G.A., Vastine, D.W., and Meisels, H.I. The experimental and clinical use of intravitreal antibiotics to treat bacterial and fungal endophthalmitis. Doc. Ophthalmol. 39:183-201, 1975.
17. Morgan, B.S., Larson, B., Peyman, G.A., et al. Toxicity of antibiotic combinations for vitrectomy infusion fluid. Ophthalmic. Surg. 10:74-77, 1979.
18. Daily, M.J., Peyman, G.A., and Fishman, G. Intravitreal injection of methicillin for treatment of endophthalmitis. Am. J. Ophthalmol. 76:343-350, 1973.
19. May, D.R., Ericson, E.S., Peyman, G.A., et al. Intraocular injection of gentamicin: Single injection therapy of experimental bacterial endophthalmitis. Arch. Ophthalmol. 91:487-489, 1974.
20. Schenk, A.G., and Peyman, G.A. Lincomycin by direct intravitreal injection in the treatment of experimental bacterial endophthalmitis. Albrecht von Graefes Arch. Klin. Exp. Ophthalmol. 190:281-291, 1974.
21. Bennett, T.O., and Peyman, G.A. Use of tobramycin in eradicating experimental bacterial endophthalmitis. Albrecht von Graefes Arch. Klin. Exp. Ophthalmol. 191:93-107, 1974.
22. Peyman, G.A., Nelsen, P., and Bennett, T.O. Intravitreal injection of kanamycin in experimentally induced endophthalmitis. Can. J. Ophthalmol. 9:322-327, 1974.
23. Nelsen, P., Peyman, G.A., and Bennett, T.O. BB-K8: A new aminoglycoside for intravitreal injection in bacterial endophthalmitis. Am. J. Ophthalmol. 78:82-89, 1974.
24. Koziol, J., and Peyman, G. Intraocular chloramphenicol and bacterial endophthalmitis. Can. J. Ophthalmol. 9:316-321, 1974.
25. Axelrod, A.J., Peyman, G.A., and Apple, D.J. Toxicity of intravitreal injection of amphotericin B. Am. J. Ophthalmol. 76:578-583, 1973.
26. Graham, R.O., and Peyman, G.A. Intravitreal injection of dexamethasone: Treatment of experimentally induced endophthalmitis. Arch. Ophthalmol. 92:149-154, 1974.
27. Coats, M.L., and Peyman, G.A. Intravitreal corticosteroids in the treatment of exogenous fungal endophthalmitis. Retina. 12:46-51, 1992.
28. Jonas, B. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic. Res. 38:218-245, 2006.
29. Jonas, J.B., Kamppeter, B.A., Harder, B., et al. Intravitreal triamcinolone acetonide for diabetic macular edema: A prospective, randomized study. J. Ocul. Pharmacol. Ther. 22:200-207, 2006. (Pubitemid 44051133)
30. Jonas, J.B., and Schlichtenbrede, F. Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases. Eye. 22:869-873, 2008.
31. Zhang, Z., Zhu, Z., Wang, D., et al. Low-power transpupillary thermotherapy combined with intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization. Ophthalmic. Res. 39:241-242, 2007.
32. Bakri, S.J., and Ekdawi, N.S. Intravitreal triamcinolone and bevacizumab combination therapy for refractory choroidal neovascularization with retinal angiomatous proliferation. Eye. 22:978-980, 2008.
33. Cheema, R.A., Peyman, G.A., and Fant, T., et al. Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy. Ophthalmic. Surg. Lasers. Imaging. 38:365-370, 2007.
34. Soheilian, M., Ramezani, A., Bijanzadeh, B., et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina. 27:1187-1195, 2007.
35. Fluocinolone acetonide (Retisert). Package insert. Bausch and Lomb, Rochester, NY; April 2005. Accessed September 3, 2009 at www.Bausch.com.
36. Paris, C.L., Peyman, G.A., Gremillion, C.M. Jr., et al. Intravitreal dexamethasone following vitreous surgery. Int. Ophthalmol. 15:173-174, 1991.
37. Kim, S.J., Adams, N.A., Toma, H.S., et al. Safety of intravitreal ketorolac and diclofenac. Retina. 28:595-605, 2008.
38. Margalit, E., Kugler, L.J., Brumm, M.V., et al. The safety of intraocular ketorolac in rabbits. Invest. Ophthalmol. Vis. Sci. 47:2093-2099, 2006.
39. Morales, A.M., Kivilcim, M., Peyman, G.A., et al. Intravitreal toxicity of ketorolac tris salt and flurbiprofen. OSLI. 40:38-42, 2009.
40. Kivilcim, M., Peyman, G.A., Kazi, A.A., et al. Intravitreal toxicity of high-dose etanercept. J. Ocular. Pharmacol. Therap. 23:57-62, 2007.
41. Fauser, S., Kalbacher, H., Alteheld, N., et al. Pharmacokinetics and safety of intravitreally delivered etanercept. Graefes Arch. Clin. Exp. Ophthalmol. 242:582-586, 2004.
42. Giansanti, F., Ramazzotti, M., Vannozzi, L., et al. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest. Ophthalmol. Vis. Sci. 49:1151-1156, 2008.
43. Oueghlani, E., and Pavésio, C.E. Intravitreal triamcinolone injection for unresponsive cystoid macular oedema in probable Behçet's disease as an additional therapy. Klin. Monatsbl. Augenheilkd. 225:497-499, 2008.
44. Manzano, R.P., Peyman, G.A., Carvounis, P.E., et al. Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch. Clin. Exp. Ophthalmol. 246:907-911, 2008.
45. Passos, E., Genaidy, M.M., and Peyman, G.A. Ocular toxicity of intravitreal tacrolimus. Ophthalmic. Surg. Lasers. 33:140-144, 2002.
46. Grisolano, J. Jr., and Peyman, G.A. Retinal toxicity study of intravitreal cyclosporin. Ophthalmic. Surg. 17:155-156, 1986.
47. Aydin, E., Kivilcim, M., Peyman, G.A., et al. Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular- weight heparin and doxycycline. Cornea. 27:446-453, 2008.
48. Peyman, G.A., Kazi, A.A., Riazi-Esfahani, M., et al. The effect of combinations of flurbiprofen, low molecular weight heparin, and doxycycline on the inhibition of corneal neovascularization. Cornea. 25:582-585, 2006.
49. Avdin, E., Kazi, A.A., Peyman, G.A., et al. [Retinal toxicity of intravitreal doxycycline. A pilot study.] Arch. Soc. Esp. Oftalmol. 82:223-228, 2007.
50. Pulido, J., Peyman, G.A., Leasar, T., et al. Intravitreal toxicity of hydroxyacyclovir (BW-B759U), a new antiviral agent. Arch. Ophthalmol. 103:840-841, 1985.
51. Schulman, J., Peyman, G.A., and Pulido, J. Viral retinitis and its management. Afro-Asian J. Ophthalmol. 3:143-146, 1985. (Pubitemid 15021940)
52. Vegh, S., Peyman, G.A., Vernot, J., et al. Toxicity of intravitreal interferon. Ophthalmic. Surg. 17:103-105, 1986.
53. Pang, M.P., Peyman, G.A., Nikoleit, J., et al. Intravitreal trifluorothymidine and retinal toxicity. Retina. 6:260-263, 1987.
54. She, S.-C., Peyman, G.A., and Schulman, J.A. Toxicity of intravitreal injection of foscarnet in the rabbit eye. Int. Ophthalmol. 12:151-154, 1988.
55. Peyman, G.A., Schulman, J.A., Khoobehi, B., et al. Toxicity and clearance of a combination of liposome-encapsulated ganciclovir and trifluridine. Retina. 9:232-236, 1989.
56. Schulman, J., Peyman, G.A., Horton, M.B., et al. Intraocular penetration of new antiviral agent, hydroxya-cyclovir (BW-B759U). Jap. J. Ophthalmol. 30:116-124, 1986.
57. Schulman, J., Peyman, G.A., Horton, M.B., et al. Intraocular 9-([2-hydroxy-1-(hydroxymethy)ethoxy]methyl)-guanine levels after intravitreal and subconjunctival administration. Ophthalmic. Surg. 17:429-432, 1986.
58. Felsentein, D., D'Amico, D.J., Hirsch, M.S., et al. Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1(hydroxymethyl) ethoxmethyl]guanine. Ann. Intern. Med. 103:377-380, 1985.
59. Palestine, A.G., Stevens, G. Jr., Lane, H.C., et al. Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine. Am. J. Ophthalmol. 101:95-101, 1986.
60. Freeman, W.R. Intraocular antiviral therapy. Arch. Ophthalmol. 107:1737-1739, 1989.
61. Peyman, G.A., and Schulman, J.A. Intravitreal Surgery: Principles and Practice. New York: Appleton-Century-Crofts; 1986; p. 407-455.
62. Kao, G.W., Peyman, G.A., Fiscella, R., et al. Retinal toxicity of ganciclovir in vitrectomy infusion solution. Retina. 7:80-83, 1987.
63. Pulido, J.S., Palacio, M., Peyman, G.A., et al: Toxicity of intravitreal antiviral drugs. Ophthalmic. Surg. 15:666-669, 1984.
64. Yoshizumi, M.O., Niizawa, J.M., and Meyers-Elliott, R. Ocular toxicity of intraviteral vidarabine solubilized in dimethyl sulfoxide. Arch. Ophthalmol. 104:426-430, 1986.
65. Karacorlu, S., Peyman, G.A., Karacorlu, M., et al. Retinal toxicity of 6-methoxypurine arabinoside (ara-M): A new selective and potent inhibitor of varicella-zoster virus. Retina. 12:261-264, 1992.
66. Nikoleit, J.R., Peyman, G.A., Lagouros, P., et al. Retinal toxicity of intraviteral ethyldeoxyuridine and zinc. Ann. Ophthalmol. 20:385-387, 1988.
67. Small, G.H., Peyman, G.A., Srinivasan, A., et al. Retinal toxicity of combination antiviral drugs in an animal model. Can. J. Ophthalmol. 22:300-303, 1987.
68. Peyman, G.A., Barrada, A., Greenberg, D., et al. Toxicity of antineoplastic drug combinations in vitrectomy infusion fluid. Ophthalmic. Surg. 15:844-846, 1984.
69. Barrada, A., Peyman, G.A., Case, J., et al. Evaluation of intravitreal 5-fluorouracil, vincristine, VP 16, doxorubicin, and thiotepa in primate eyes. Ophthalmic. Surg. 15:767-769, 1984.
70. Peyman, G.A., and Schulman, J. Proliferative vitreoretinopathy and chemotherapeutic agents. Surv. Ophthalmol. 29:434-442, 1985.
71. Blumenkranz, M.S., Ophis, A., Claflin, A.J., et al. Fluorouracil for the treatment of massive periretinal proliferation. Am. J. Ophthalmol. 94:458-467, 1982.
72. Kivilcim, M., Kazi, A.A., Peyman, G.A., et al. Retinal toxicity of intravitreal 5-fluorouracil in silicone-filled rabbit eyes. J. Coll. Physicians. Surg. Pak. 16:351-354, 2006.
73. Rosenfeld, P.J., Moshfeghi, A.A., and Puliafito, C.A. Optical coherance tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic. Surg. Lasers Imaging. 36:331-335, 2005.
74. Rosenfeld, P.J. Intravitreal Avastin: The low cost alternative to Lucentis? Am. J. Ophthalmol. 142:141-143, 2006.
75. Bakri, S.J., Cameron, J.D., McCannel, C.A., et al. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am. J. Ophthalmol. 142:162-164, 2006.
76. Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1419-1431, 2006.
77. Lantry, L.E. Ranibizumab, a mAb against VEGF-A for the potential treatment of age-related macular degeneration and other ocular complications. Curr. Opin. Mol. Ther. 9:592-602, 2007.
78. Kourlas, H., and Abrams, P. Ranibizumab for the treatment of neovascular age-related macular degeneration: A review. Clin. Ther. 29:1850-1861, 2007.
79. Augustin, A.J., and Offermann, I. Combination therapy for choroidal neovascularisation. Drugs. Aging. 24:979-990, 2007.
80. Chang, T.S., Bressler, N.M., Fine, J.T., et al. Improved visionrelated function after ranibizumab treatment of neovascular age-related macular degeneration: Results of a randomized clinical trial. Arch. Ophthalmol. 125:1460-1469, 2007.
81. Brown, M.M., Brown, G.C., Brown, H.C., et al. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology. 115:1039-1045, 2008.
82. Luthra, S., Narayanan, R., Marques, L.E., et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina. 26:512-518, 2006.
83. Maturi, R.K., Bleau, L.A., and Wilson, D.L. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina. 26:270-274, 2006.
84. Shahar, J., Avery, R.L., Heilweil, G., et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 26:262-269, 2006.
85. Manzano, R.P., Peyman, G.A., Khan, P., et al. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 26:257-261, 2006.
86. Salinson, R.C., and Harris, A.L. Anti DII4 therapy: Can we block tumor growth by increasing angiogenesis? Trends Mol. Med. 3:389-405, 2007.
87. Bertolini, F., Shaked, Y., Mancuso, P., et al. The multifaceted circulating endothelial cell in cancer: Towards marker and target identification. Nat. Rev. Cancer. 6:835-845, 2006.
88. Pauleikhoff, D., Bornfeld, N., Gabel, V.P., et al. [The Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists- Comments on the current therapy for neovascular AMD]. Klin. Monatsbl. Augenheilkd. 222:381-388, 2005.
89. Spaide, R.F., Sorenson, J., and Maranan, L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 112:301-304, 2005. (Pubitemid 40202568)
90. Smithen, L.M., and Spaide, R.F. Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am. J. Ophthalmol. 138:884-885, 2004.
91. Hunter, M.A., Dunbar, M.T., and Rosenfeld, P.J. Retinal angiomatous proliferation: Clinical characteristics and treatment options. Optometry. 75:577-588, 2004.
92. Rechtman, E., Danis, R.P., Pratt, L.M., et al. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br. J. Ophthalmol. 88:344-347, 2004.
93. Spaide, R.F., Sorenson, J., and Maranan, L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 110:1517-1525, 2003.
94. Heier, J.S., Boyer, D.S., Ciulla, T.A., et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the FOCUS Study. Arch. Ophthalmol. 124:1532-1542, 2006 [erratum appears in Arch. Ophthalmol. 125:138, 2007].
95. Antoszyk, A.N., Tuomi, L., Chung, C.Y., et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): Year 2 results. Am. J. Ophthalmol. 145:862-874, 2008.